Home » Mauricio Arcos-Burgos.

Mauricio Arcos-Burgos.

Horia C. Stanescu, M uk pharmacy .D., Mauricio Arcos-Burgos, M.D., Ph.D., Alan Medlar, M.Sc., Detlef Bockenhauer, M.D., Ph.D., Anna Kottgen, M.D., M.P.H., Liviu Dragomirescu, Ph.D., Catalin Voinescu, B.Sc., Naina Patel, B.Sc., Kerra Pearce, M.Sc., Mike Hubank, Ph.D., Henry A.F. Stephens, Ph.D., Valerie Laundy, F.I.M.L.S., Sandosh Padmanabhan, M.D., Ph.D., Anna Zawadzka, Julia M. Hofstra, M.D., Marieke J.H. Coenen, Ph.D., Martin den Heijer, M.D., Ph.D., Lambertus A.L.M. Kiemeney, Ph.D., Delphine Bacq-Daian, M.Sc., Benedicte Stengel, M.D., Ph.D., Stephen H.

We also carried out a post hoc sensitivity evaluation where deaths were regarded as recurrences. SAS for Home windows software, edition 9.1 , was used to perform all statistical analyses. A P value of less than 0.05 was thought to indicate statistical significance.). A complete of 75 infants had been assigned to endure intravitreal bevacizumab monotherapy randomly, and 75 to typical laser therapy. Table 1Table 1Risk Factors and Other Characteristics of Infants with Zone I Retinopathy of Prematurity or Area II Posterior ROP, According to Treatment Group. Lists clinical features of infants and risk elements for retinopathy of prematurity. One protocol violation occurred, involving an infant with zone I disease who was simply randomly designated to the conventional laser beam therapy group but was rather treated with intravitreal bevacizumab.